homepage hero
Scroll down
Stasis to peristalsis

Enhanced colonic peristalsis is possible with Motegrity, the only FDA-approved selective serotonin type 4 (5-HT4) receptor agonist for adults with CIC.1-4

SELECT IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Wondering if your patients are
looking for a different approach?

This Patient ID tool may help uncover if they are interested in a treatment that works differently.

Help your patients save on Motegrity

With the Motegrity savings card, eligible patients can pay as little as $15* per 30-day or 90-day fill.

*Up to $90 max benefit per 30-day prescription; $325 max benefit per 90-day prescription. Terms and conditions apply. See link above for details.

Calendar icon

Clinical Efficacy

View the results established in 6 clinical trials in 2484 patients with CIC.1

See trial data
Bottle icon

Request Samples

Interested in receiving samples of Motegrity?

Request samples
Map icon

Insurance Access for Patients

IMPORTANT SAFETY INFORMATION

Contraindications

  • Hypersensitivity to Motegrity. Reactions including dyspnea, rash, pruritus, urticaria, and facial edema have been observed
  • Intestinal perforation or obstruction due to structural or functional disorder of the gut wall, obstructive ileus, severe inflammatory conditions of the intestinal tract such as Crohn’s disease, ulcerative colitis, and toxic megacolon/megarectum

Warnings and Precautions

Suicidal Ideation and Behavior: In clinical trials, suicides, suicide attempts and suicidal ideation have been reported. Postmarketing cases of suicidal ideation and behavior as well as self-injurious ideation and new onset or worsening of depression have been reported within the first few weeks of starting Motegrity. A causal association between treatment with Motegrity and an increased risk of suicidal ideation and behavior has not been established. Monitor patients for new onset or worsening of depression and emergence of suicidal thoughts and behavior. Instruct patients to discontinue Motegrity immediately and contact their healthcare provider if they experience any of these symptoms.

Adverse Reactions

Most common adverse reactions (≥2%) are headache, abdominal pain, nausea, diarrhea, abdominal distension, dizziness, vomiting, flatulence, and fatigue.

Use in Specific Populations

  • Lactation: Motegrity is present in breast milk. Consider risks and benefits of breastfeeding
  • Pediatric: Safety and effectiveness in pediatric patients have not been established
  • Renal Impairment: A decreased dosage is recommended in patients with severe renal impairment. Avoid Motegrity in patients with end-stage renal disease requiring dialysis

INDICATION

Motegrity is indicated for the treatment of chronic idiopathic constipation (CIC) in adults.

Please click here for full Prescribing Information.

References:

1. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc. 2. Emmanuel A, Cools M, Vandeplassche L, Kerstens R. Am J Gastroenterol. 2014;109(6):887-894. 3. Miner PB, Camilleri M, Burton D, et al. Neurogastroenterol Motil. 2016;28(9):1341-1348. 4. Enterostasis. Stedman's Online. https://stedmansonline.com/‌content.aspx‌?term=‌ENTEROSTASIS. Accessed February 25, 2019.